Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.81 |
| ▸ | ESR1 | P03372 | 6/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.52 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | ESRRB | O95718 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12574644 | 1.00 | CYP19A1 (0.81) | CYP19A1ESR1ESR2LMNASMN1; SMN2 | |
| SCHEMBL20626542 | 0.99 | CYP19A1 (0.80) | CYP19A1ESR1ESR2LMNASMN1; SMN2 | |
| SCHEMBL12574723 | 0.96 | CYP19A1 (0.85) | CYP19A1ESR1ESR2LMNASMN1; SMN2 | |
| SCHEMBL22925322 | 0.92 | CYP19A1 (0.78) | CYP19A1ESR1ESR2LMNASMN1; SMN2 | |
| SCHEMBL18798668 | 0.92 | CYP19A1 (0.78) | CYP19A1ESR1ESR2LMNASMN1; SMN2 | |
| SCHEMBL12544797 | 0.92 | CYP19A1 (0.78) | CYP19A1ESR1ESR2LMNASMN1; SMN2 | |
| SCHEMBL2840052 | 0.92 | CYP19A1 (0.78) | CYP19A1ESR1ESR2LMNASMN1; SMN2 | |
| SCHEMBL20990401 | 0.92 | CYP19A1 (0.78) | CYP19A1ESR1ESR2LMNASMN1; SMN2 | |
| SCHEMBL18104337 | 0.92 | CYP19A1 (0.78) | CYP19A1ESR1ESR2LMNASMN1; SMN2 | |
| SCHEMBL12690918 | 0.92 | CYP19A1 (0.78) | CYP19A1ESR1ESR2LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723757-B2 | 6-substituted estradiol derivatives and methods of use | ENDECE LLC (US) | 2020-07-28 | — | — | US | claimed |
| US-20190135853-A1 | 6-Substituted Estradiol Derivatives and Methods of Use | ENDECE LLC | 2019-05-09 | — | — | US | claimed |
| US-9636348-B2 | 6-substituted estradiol derivatives for use in remyelination of nerve axons | ENDECE LLC (US) | 2017-05-02 | — | — | US | claimed |
| US-20160279144-A1 | 6-Substituted Estradiol Derivatives for Use in Remyelination of Nerve Axons | ENDECE LLC | 2016-09-29 | — | — | US | claimed |
| US-9364486-B2 | 6-substituted estradiol derivatives for use in remyelination of nerve axons | ENDECE LLC (US) | 2016-06-14 | — | — | US | claimed |
| EP-2688570-B1 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES FOR USE IN REMYELINATION OF NERVE AXONS | ENDECE LLC (US) | 2015-11-18 | — | — | EP | claimed |
| US-20150265630-A1 | 6-Substituted Estradiol Derivatives for the Treatment of Alzheimer's Disease | ENDECE LLC | 2015-09-24 | — | — | US | claimed |
| US-20120245131-A1 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES FOR USE IN REMYELINATION OF NERVE AXONS | ENDECE, LLC | 2012-09-27 | — | — | US | claimed |
| US-20100130463-A1 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE | ENDECE, LLC | 2010-05-27 | — | — | US | claimed |
| US-20230097440-A1 | METHODS FOR MODULATION OF LIPOPROTEIN LIPASE AND APOLIPOPROTEIN C2 EXPRESSION AND/OR ACTIVITY IN THE TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM TISSUE DISEASE STATES | ENDECE LLC | 2023-03-30 | — | — | US | disclosed |
| US-20210024568-A1 | METHODS FOR MODULATION OF LIPOPROTEIN LIPASE AND APOLIPOPROTEIN C2 EXPRESSION AND/OR ACTIVITY IN THE TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM TISSUE DISEASE STATES | ENDECE LLC | 2021-01-28 | — | — | US | disclosed |
| US-10723757-B2 | 6-substituted estradiol derivatives and methods of use | ENDECE LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190135853-A1 | 6-Substituted Estradiol Derivatives and Methods of Use | ENDECE LLC | 2019-05-09 | — | — | US | disclosed |
| US-10174070-B2 | 6-substituted estradiol derivatives and methods of use | ENDECE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-9364486-B2 | 6-substituted estradiol derivatives for use in remyelination of nerve axons | ENDECE LLC (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2507253-B1 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE | ENDECE LLC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2688570-B1 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES FOR USE IN REMYELINATION OF NERVE AXONS | ENDECE LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-20150265630-A1 | 6-Substituted Estradiol Derivatives for the Treatment of Alzheimer's Disease | ENDECE LLC | 2015-09-24 | — | — | US | disclosed |
| US-20120245131-A1 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES FOR USE IN REMYELINATION OF NERVE AXONS | ENDECE, LLC | 2012-09-27 | — | — | US | disclosed |
| US-20100130463-A1 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE | ENDECE, LLC | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723757-B2 | 6-substituted estradiol derivatives and methods of use | SHBG, HSD17B11, CYP19A1 | CYP19A1 3/4885ESR1 5/4885ESR2 4/4885 |
| US-20190135853-A1 | 6-Substituted Estradiol Derivatives and Methods of Use | SHBG, HSD17B11, CYP19A1 | CYP19A1 3/4885ESR1 5/4885ESR2 4/4885 |
| US-20230097440-A1 | METHODS FOR MODULATION OF LIPOPROTEIN LIPASE AND APOLIPOPROTEIN C2 EXPRESSION AND/OR ACTIVITY IN THE TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM TISSUE DISEASE STATES | LPL, LIPE, PMP22 | CYP19A1 236/4885ESR1 623/4885ESR2 59/4885 |
| US-20150265630-A1 | 6-Substituted Estradiol Derivatives for the Treatment of Alzheimer's Disease | HSD17B11, ESR2, PSEN2 | CYP19A1 5/4885ESR1 13/4885ESR2 2/4885 |
| US-10174070-B2 | 6-substituted estradiol derivatives and methods of use | NR3C2, SHBG, NR5A1 | CYP19A1 51/4885ESR1 17/4885ESR2 5/4885 |
| US-20160279144-A1 | 6-Substituted Estradiol Derivatives for Use in Remyelination of Nerve Axons | PMP22, GAP43, MAG | CYP19A1 59/4885ESR1 199/4885ESR2 13/4885 |
| US-20210024568-A1 | METHODS FOR MODULATION OF LIPOPROTEIN LIPASE AND APOLIPOPROTEIN C2 EXPRESSION AND/OR ACTIVITY IN THE TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM TISSUE DISEASE STATES | LPL, LIPE, PMP22 | CYP19A1 236/4885ESR1 623/4885ESR2 59/4885 |
| US-20120245131-A1 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES FOR USE IN REMYELINATION OF NERVE AXONS | PMP22, GAP43, MAG | CYP19A1 59/4885ESR1 199/4885ESR2 13/4885 |
| US-20100130463-A1 | 6-SUBSTITUTED ESTRADIOL DERIVATIVES AND METHODS OF USE | NR3C2, SHBG, ESR2 | CYP19A1 50/4885ESR1 17/4885ESR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.